Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)  by Qunibi, Wajeh Y. et al.
Kidney International, Vol. 65 (2004), pp. 1914–1926
Treatment of hyperphosphatemia in hemodialysis patients: The
Calcium Acetate Renagel Evaluation (CARE Study)
WAJEH Y. QUNIBI, ROBERT E. HOOTKINS, LAVETA L. MCDOWELL, MICAH S. MEYER,
MATTHIAS SIMON, RODOLFO O. GARZA, RUSSELL W. PELHAM, MARK V.B. CLEVELAND,
LARRY R. MUENZ, DAVID Y. HE, and CHARLES R. NOLAN
Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas; Austin Diagnostic Clinic,
Austin, Texas; Braintree Laboratories, Braintree, Massachusetts; and Larry R. Muenz & Associates, Gaithersburg, Maryland
Treatment of hyperphosphatemia in hemodialysis patients: The
Calcium Acetate Renagel Evaluation (CARE Study).
Background. Hyperphosphatemia underlies development of
hyperparathyroidism, osteodystrophy, extraosseous calcifica-
tion, and is associated with increased mortality in hemodialysis
patients.
Methods. To determine whether calcium acetate or sevelamer
hydrochloride best achieves recently recommended treatment
goals of phosphorus ≤5.5 mg/dL and Ca × P product ≤55
mg2/dL2, we conducted an 8-week randomized, double-blind
study in 100 hemodialysis patients.
Results. Comparisons of time-averaged concentrations
(weeks 1 to 8) demonstrated that calcium acetate recipients had
lower serum phosphorus (1.08 mg/dL difference, P = 0.0006),
higher serum calcium (0.63 mg/dL difference, P < 0.0001), and
lower Ca × P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer
recipients. At each week, calcium acetate recipients were 20%
to 24% more likely to attain goal phosphorus [odds ratio (OR)
2.37, 95% CI 1.28–4.37, P = 0.0058], and 15% to 20% more
likely to attain goal Ca × P (OR 2.16, 95% CI 1.20–3.86, P =
0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%)
calcium acetate recipients, all of whom received concomitant
intravenous vitamin D. By regression analysis hypercalcemia
was more likely with calcium acetate (OR 6.1, 95% CI 2.8–13.3,
P < 0.0001). Week 8 intact PTH levels were not significantly dif-
ferent. Serum bicarbonate levels were significantly lower with
sevelamer hydrochloride treatment (P < 0.0001).
Conclusion. Calcium acetate controls serum phosphorus and
calcium-phosphate product more effectively than sevelamer hy-
drochloride. Cost-benefit analysis indicates that in the absence
of hypercalcemia, calcium acetate should remain the treatment
of choice for hyperphosphatemia in hemodialysis patients.
Hyperphosphatemia is associated with increased mor-
tality in hemodialysis patients and plays a key role in the
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development of hyperparathyroidism, renal osteodystro-
phy, and extraosseous calcification. Serum phosphorus
exceeding 5.5 mg/dL, and calcium phosphate product
(Ca × P) over 52 mg2/dL2 each correlate with increased
mortality risk in dialysis patients [1]. These findings have
led to recent recommendations for more rigorous control
of serum phosphorus to between 2.5 and 5.5 mg/dL, while
maintaining Ca × P product less than 55 mg2/dL2 [2].
Because dietary phosphorus restriction and hemodial-
ysis often fail to adequately control serum phosphorus,
phosphate binders are routinely prescribed to reduce
intestinal absorption of phosphate. Although effective,
aluminum-containing binders have largely been aban-
doned because of risks of aluminum intoxication [3].
Calcium acetate is the most commonly prescribed
calcium-containing phosphate binder in the United
States. Sevelamer hydrochloride is a recently introduced
phosphate binder that is a quaternary amine anion ex-
change resin that contains no calcium or aluminum [4].
Various open-label studies have shown that both calcium
acetate and sevelamer reduce serum phosphorus levels
in hemodialysis patients [4–8]. However, in most of these
studies, hyperphosphatemic dialysis patients treated with
sevelamer have not reliably achieved the newly recom-
mended treatment goal for serum phosphorus. Control of
serum phosphorus to normal levels is clearly important
for prevention and treatment of secondary hyperparathy-
roidism, and has the potential to reduce cardiovascular
risk in dialysis patients. We, therefore, conducted a ran-
domized double-blind study to compare the efficacy of
calcium acetate and sevelamer hydrochloride for serum
phosphorus control in patients with end-stage renal dis-
ease (ESRD) on maintenance hemodialysis.
METHODS
Study design
The Calcium Acetate Renagel Evaluation (CARE
Study) was a prospective, multicenter, randomized,
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double-blind study comparing the efficacy of calcium ac-
etate and sevelamer hydrochloride for the treatment of
hyperphosphatemia in patients with ESRD on hemodial-
ysis. The study was conducted at six outpatient clinics as-
sociated with two study centers: the University of Texas
Health Sciences Center at San Antonio (San Antonio,
TX, USA), and the Austin Diagnostic Clinic (Austin,
TX, USA). The protocol was approved by the respec-
tive Institutional Review Boards. Enrolled patients con-
sisted of 100 adults receiving maintenance hemodialysis
for at least 3 months, receiving a stable dose of phos-
phate binder and intravenous vitamin D for at least one
month. Main exclusion criteria were intact parathyroid
hormone (iPTH) level over 1000 pg/mL, or a history of
previous parathyroidectomy. Patients whose serum phos-
phorus was ≥6.0 mg/dL after 1 to 3 weeks of binder
withdrawal were randomized to 8-week treatment with
either calcium acetate (PhosLo 667 mg capsules; Brain-
tree Laboratories, Braintree, MA, USA) or sevelamer
hydrochloride (Renagel 403 mg capsules; Genzyme
Corporation, Cambridge, MA, USA). Study blinding
was maintained by packaging calcium acetate in hard
gelatin capsules identical to the sevelamer hydrochlo-
ride capsules. The starting dose of study medication
was based on package insert recommendations indexed
to serum phosphorus at the end of washout as fol-
lows: ≥6 mg/dL and <7.5 mg/dL, 2 capsules thrice
daily; ≥7.5 mg/dL and <9.0 mg/dL, 3 capsules thrice daily;
≥9.0 mg/dL, 4 capsules thrice daily. Study drug was ad-
ministered with meals, with one half the dose immedi-
ately before, and the other half immediately after the
meal. Each week the dosage of study drug was increased
1 to 2 capsules per meal as needed to achieve a goal
serum phosphorus ≤5.5 mg/dL. Dosage adjustment was
based only on the serum phosphorus without regard to
the Ca × P product. If the serum calcium level exceeded
11.0 mg/dL, binder dose was decreased by one capsule
per meal. Dialysate calcium concentration (2.5 mEq/
L) and prestudy intravenous vitamin D dosage were
held constant during the study. At enrollment, patients
were counseled with regard to a phosphorus-restricted
diet, and instructed to maintain that diet throughout the
course of the study. Except as outlined above, patients
were prohibited from consuming calcium supplements
or antacids containing aluminum, magnesium, or cal-
cium. Study drug compliance was assessed by weekly pill
counts. Each week, subjects graded their subjective symp-
toms of constipation, nausea, vomiting, diarrhea, and
abdominal pain on a scale of 0 (none) to 10 (severe).
Predialysis blood samples were obtained weekly for de-
termination of phosphorus, calcium, and bicarbonate. At
weeks 0 (baseline), 4, and 8, intact parathyroid hormone
(iPTH) levels were measured. Laboratory analyses were
performed at a central reference laboratory. Projected an-
nual costs of phosphate binder treatment were calculated
based on the mean binder dose at week 8 and average
wholesale prices.
Statistical methods
Weekly serum phosphorus, serum calcium, and cal-
cium × phosphorus product (Ca × P) were described
by their mean values, as well as by a binary treatment
outcome of “goal attained or not.” For serum calcium,
a three-level outcome (hypocalcemia, normal serum cal-
cium, and hypercalcemia) was also used. Primary analy-
ses were repeated measures regressions, a logistic model
for binary outcomes, and a proportional odds model for
the three-level, repeated ordinal outcome. These models
were implemented in SAS/STAT software PROC GEN-
MOD (version 8.2, SAS Institute, Cary, NC, USA). Treat-
ment effects were assessed by their odds ratio (OR), but
simpler percentage differences were also given because
they were roughly constant over time for serum phospho-
rus and Ca × P product. Each week’s serum phospho-
rus level was coded as “goal attained” for P ≤5.5 mg/dL,
and similarly for serum calcium, but with the goal of 8.5
mg/dL ≤Ca≤ 11 mg/dL. A three-level ordinal outcome
for serum calcium was also defined by the same limits.
For Ca × P product to be coded as “goal attained,” the
product had to be ≤55 mg2/dL2, and the binary goals
for serum phosphorus and serum calcium also had to be
attained. Repeated measures models included linear and
quadratic terms in time (the latter to allow for curved tra-
jectories), a binary indicator for treatment (calcium ac-
etate vs. sevelamer hydrochloride), and baseline values
of the quantitative outcome and of iPTH level, weight,
age, gender, and study center. Interactions among treat-
ment, time, and center were also examined. Autoregres-
sive correlation structure was assumed. All subjects and
observations were included (intention-to-treat analysis).
Time was included in models as 1, 2, . . ., 8 weeks, ex-
cept for a set of models that omitted the first four weeks
of outcomes in order to focus on longer-term responses
after the initial four weeks of study drug titration. No im-
putation was used but sensitivity analyses examined the
impact of setting all missing values to “goal attained,” or
all to “goal not attained,” and also included compliance as
defined by weekly percent of pills taken. Significant treat-
ment effects were defined by likelihood ratio P values of
0.05 or less for treatment main effects, or, as appropri-
ate, combined main effects and interactions of treatment
with time. Similar repeated measures models were used
to analyze continuous and binary serum bicarbonate out-
comes. Time to first attainment of treatment goals was de-
scribed by Kaplan-Meier curves, and compared between
treatment groups by log-rank test (SAS Institute). Addi-
tional analyses of each outcome concerned the propor-
tion of eight study weeks with the goal attained. Failure
was assumed in weeks with missing data. Treatments were
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Table 1. Demographics and baseline laboratory parametersa
Calcium Sevelamer P
Parameter acetate HCl valuec
Number of patients 48 50
Age years 53.9 ± 13.3 52.3 ± 14.7 0.57
Predialysis weight kg 76.8 ± 18.7 85.5 ± 22.5 0.040
Gender 0.82
Male 28 (58%) 28 (56%)
Female 20 (42%) 22 (44%)
Race 0.74
Hispanic 26 (54%) 24 (48%)
Black 15 (31%) 14 (28%)
White 7 (15%) 12 (24%)
Years on dialysis 3.7 ± 2.7 4.8 ± 6.5 0.28
Vitamin D therapy 31 (65%) 30 (60%) 0.64
Prestudy binder 0.079
Calcium-based alone 33 (69%) 26 (52%)
Sevelamer alone 5 (10%) 6 (12%)
More than one binder 10 (21%) 18 (36%)
Baseline laboratory datab
Serum phosphorus mg/dL 7.7 ± 1.8 7.7 ± 2.0 0.99
Serum calcium mg/dL 8.9 ± 0.9 8.9 ± 0.7 0.84
Ca × P product mg2/dL2 69.0 ± 17.3 69.5 ± 19.4 0.91
Intact PTH pg/mL 257.3 ± 160.6 206.1 ± 125.7 0.15d
Serum bicarbonate mEq/L 19.6 ± 2.5 20.5 ± 3.0 0.11
aPlus minus values are mean ± SD.
bBaseline laboratory data were obtained at the end of 1- to 3-week washout
period off all phosphate binders.
cThe Cochran-Mantel-Haenszel chi-square was used to assess treatment group
differences for categorical data. Student t test was used to compare means.
dP value obtained from comparison of log10-transformed values.
compared by exact Cochran-Mantel-Haenszel test, and
also by proportional odds regression (SAS Institute), with
the same baseline covariates as for the repeated measures
model. To summarize weekly means for serum phospho-
rus, calcium, and Ca × P product, each subject’s quantita-
tive outcomes were averaged to produce three values of
Cavg, computed by trapezoidal rule area-under-the-curve,
excluding baseline, divided by follow-up time. Between-
treatment comparisons of Cavg were by linear regression
(SAS Institute), again with the same baseline covariates.
Similar linear models were used for iPTH outcomes.
RESULTS
Demographics and baseline laboratory comparisons
A total of 128 patients with ESRD on maintenance
hemodialysis were screened for enrollment. There were
28 potential subjects who failed screening for the fol-
lowing reasons: 16 had serum phosphorus less than 6.0
mg/dL after a 3-week washout period off of phosphate
binders; 4 patients refused study participation; 3 had a
history of questionable compliance with medications; 4
had previous parathyroidectomy; and 1 patient had no
requirement for binder therapy for phosphorus control.
One hundred patients were enrolled; however, two pa-
tients in the calcium acetate group were dropped from the
study because they inadvertently resumed their prestudy
phosphate binder. Forty-eight patients were randomized
to calcium acetate, and 50 to sevelamer hydrochloride,
with 96% and 90% completing the study with no missing
postbaseline visit (P value 0.44 by Fisher exact test). Each
study center had 49 patients who were included in the
analysis. Patient demographics and baseline laboratory
comparisons are shown in Table 1. Although a statisti-
cally significant between-group difference in weight was
identified, this difference had no effect on the primary
“goal attained” outcomes (Table 2). No baseline labora-
tory measures differed significantly between treatment
groups. Bicarbonate was also analyzed as an outcome.
Baseline iPTH (after log10 transformation) was also in-
cluded as a covariate for all outcomes in the repeated
measures logistic regression model (Table 2).
Weekly means and average concentrations (Cavg) for
serum phosphorus, serum calcium, and Ca × P product
Weekly mean values for the three outcomes are dis-
played in Figures 1A, Figures 2A, and Figures 3A. Cal-
cium acetate–treated subjects had significantly lower
mean serum phosphorus (Fig. 1A), higher mean serum
calcium (Fig. 2A), and lower mean Ca × P product
(Fig. 3A). Summarizing these weekly values, average con-
centrations were computed for each patient. Means and
standard deviations of Cavg by outcome and treatment
group are shown in Table 3, both for weeks 1 to 8 and
weeks 5 to 8. Covariate-adjusted comparisons of Cavg be-
tween treatment groups show that, during weeks 1 to 8,
in the calcium acetate group, mean serum phosphorus
was lower (1.08 mg/dL difference, P value 0.0006), mean
serum calcium was higher (0.63 mg/dL difference, P value
< 0.0001), and mean Ca × P product was lower (6.1 mg2/
dL2 difference, P value 0.022). During weeks 5 to 8, treat-
ment effects on Cavg for phosphorus and calcium were
significant and similar to the effects for weeks 1 to 8, but
there was no significant treatment effect on Ca × P.
Attainment of binary treatment goals over weeks
1 to 8 and 5 to 8
In both treatment groups, median times to first attain-
ment of the binary treatment goals were two weeks for
serum phosphorus, less than one week for serum calcium,
and 3 to 4 weeks for Ca × P product, with no signif-
icant treatment effects. Repeated measures regression
models for weeks 1 to 8 and, separately, for weeks 5 to
8 agreed well with the observed weekly proportions of
“goal attained” for serum phosphorus and Ca × P prod-
uct, but less well for serum calcium (Table 2, Figs. 1B,
2B, and 3B). Beginning one week after the start of treat-
ment, in each week’s observation, calcium acetate recip-
ients were 20% to 24% more likely to attain the serum
phosphorus goal (weeks 1 to 8: summary OR 2.37, 95%
CI 1.28–4.37, treatment P value 0.0058; weeks 5 to 8:
treatment P value 0.016) (Fig. 1B). An alternative, less
stringent goal for serum phosphorus was defined by
a threshold of 6.5 mg/dL. At each postbaseline week,
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Table 2. Details of repeated measures logistic regression models for primary “goal attained” outcomes
Phosphorusa Calciumb Ca × P productc
Covariates Parameter estimate P value Parameter estimate P value Parameter estimate P value
Main effects
Intercept −0.886 0.64 −4.585 0.21 −1.600 0.39
Drug: calcium acetate 0.862 0.0058 0.791 0.31 0.769 0.0097
Week 0.563 0.0005 −0.244 0.34 0.399 0.012
Week-squared −0.051 0.0020 0.044 0.14 −0.034 0.044
Baseline outcome −0.367 0.0004 0.732 0.010 −0.033 0.0014
Baseline iPTH (log10) 1.126 0.11 −0.053 0.94 1.005 0.11
Age 0.016 0.24 −0.004 0.76 0.008 0.50
Gender: female −0.269 0.42 −0.174 0.62 −0.201 0.53
Weight −0.009 0.26 −0.002 0.76 −0.004 0.55
Center −0.589 0.076 0.007 0.98 −0.319 0.32
Interactiond between drug
(calcium acetate) and Week 0.165 0.66
Week-squared −0.043 0.31
aGoal serum phosphorus ≤5.5 mg/dL.
bGoal serum calcium equals 8.5–11 mg/dL.
cGoal serum calcium × phosphorus product ≤55 mg2/dL2.
dAlthough individual interaction term was not significant, the combined interaction effect of two terms was significant at P value of 0.019.
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Fig. 1. Serum phosphorus control with cal-
cium acetate or sevelamer hydrochloride.
Mean (±SE) serum phosphorus levels at base-
line and weekly during treatment with ei-
ther calcium acetate (open circles) or seve-
lamer hydrochloride (closed diamonds) (A).
At baseline, mean serum phosphorus levels
were not significantly different between the
two groups (P = 0.99). Calcium acetate re-
duced mean serum phosphorus below the tar-
get level of 5.5 mg/dL by the third week of
treatment, and maintained serum phosphorus
below the target level until week 8. In the seve-
lamer hydrochloride treatment group, mean
serum phosphorus never fell below the tar-
get level throughout the 8-week treatment pe-
riod. Overall, serum phosphorus levels were
significantly lower during treatment with cal-
cium acetate than during treatment with seve-
lamer hydrochloride (1.08 mg/dL difference
in Cavg during weeks 1 to 8, P value 0.0006
by covariate-adjusted regression). To con-
vert values for phosphorus to millimoles per
liter, multiply by 0.32. Observed and model-
estimated percent of subjects achieving goal
serum phosphorus level (≤5.5 mg/dL) by
treatment group and week (B). Main treat-
ment effect P = 0.0058 (all weeks), and 0.016
for weeks 5 to 8 only.
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Fig. 2. Serum calcium levels during treat-
ment with calcium acetate or sevelamer hy-
drochloride. Mean (±SE) serum calcium lev-
els at baseline and weekly during treatment
with either calcium acetate (open circles) or
sevelamer hydrochloride (closed diamonds)
(A). At baseline, mean serum calcium was
not significantly different between the two
groups (P = 0.84). Overall, serum calcium lev-
els were significantly higher during treatment
with calcium acetate than with sevelamer hy-
drochloride (0.63 mg/dL difference in Cavg
during weeks 1 to 8, P value < 0.0001 by
covariate-adjusted regression). During treat-
ment with either binder, mean serum calcium
levels remained within the normal range of
8.5 to 11 mg/dL. To convert values for cal-
cium to millimoles per liter, multiply by 0.25.
Observed and model-estimated percent of
subjects achieving goal serum calcium level
(between 8.5 to 11 mg/dL) by treatment group
and week (B). Main treatment effects: P value
= 0.16 (all weeks), 0.79 (weeks 5 to 8 only).
Combined treatment-by-week interaction: P
value = 0.019.
calcium acetate recipients were 10% to 30% more likely
to be below the threshold than sevelamer recipients,
yielding a figure (not shown) similar to Figure 1B, but
10% to 20% higher in each week. A repeated measures
model, adjusted for the baseline variables previously
cited, showed a significant benefit for calcium acetate
(main effect P value 0.0043, no significant treatment by
time interaction). Calcium acetate recipients were 15%
to 20% more likely to attain the Ca × P goal in each
week (weeks 1 to 8: summary OR 2.16, 95% CI 1.20–
3.86, treatment P value 0.0097, weeks 5 to 8: treatment
P value 0.054) (Fig. 3B). Results for calcium were more
complex because with the binary goal, there was a sig-
nificant treatment by time interaction (likelihood ratio P
value 0.019) (Fig. 2B). Main effects of treatment were not
significant for the serum calcium goal, but proportions at-
taining the serum calcium goal were higher in weeks 1 to
5 for calcium acetate recipients, and higher in weeks 6 to
8 for sevelamer hydrochloride recipients (weeks 1 to 8
and 5 to 8: treatment main effect P values 0.16 and 0.79).
All treatment comparisons were adjusted for age, gender,
weight, and baseline iPTH, but these were never signifi-
cant (Table 2). With two study centers, there was a nearly
significant center effect for phosphorus (center effect OR
1.80, 95% CI 0.94–3.46, P value 0.076, not adjusted for
compliance), but there were no significant treatment-by-
center interactions for any outcome. Analyses for missing
values had no significant impact upon treatment results.
Analysis of total number of weeks with treatment
goals attained
The number of subjects by treatment group attaining
the treatment goals for a given number of weeks is shown
in Table 4. For example, 8 calcium acetate recipients and
18 sevelamer hydrochloride recipients attained the treat-
ment goal for serum phosphorus for 0 weeks (i.e., never
attained serum phosphorus less than 5.5 mg/dL). An
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Fig. 3. Calcium × phosphorus products dur-
ing treatment with calcium acetate or seve-
lamer hydrochloride. Mean serum calcium ×
phosphorus product at baseline and weekly
during treatment with either calcium acetate
(open circles) or sevelamer hydrochloride
(closed diamonds) (A). At baseline, Ca ×
P product was not significantly different be-
tween the two groups (P = 0.91). However,
Ca × P product was significantly lower during
treatment with calcium acetate than with seve-
lamer hydrochloride (6.1 mg2/dL2 difference
in Cavg during weeks 1 to 8, P value < 0.0001
by covariate-adjusted regression). To convert
from units of mg2/dL2 to mmol2/L2, multiply
by 0.08. Observed and model-estimated per-
cent of subjects achieving goal Ca × P prod-
uct (≤55 mg2/dL2, as well as individual goals
for serum phosphorus and serum calcium) by
treatment group and week (B). Main treat-
ment effect: P value = 0.010 (all weeks), 0.054
(weeks 5 to 8 only).
exact Cochran-Mantel-Haenszel trend test significantly
favored calcium acetate for both serum phosphorus goal
and Ca × P product goal, but was not significant for serum
calcium goal. A post hoc observation is that nearly 4 of 5
of the calcium acetate recipients attained the phosphorus
goal rarely (0 to 1 weeks) or almost always (6 to 8 weeks).
Among the 37 calcium acetate recipients in these extreme
groups, significant or nearly significant predictors of
successful serum phosphorus control were greater com-
pliance and center (logistic regression OR for summary
percent compliance: 1.07, CI 1.01–1.14, P value 0.035;
OR for center: 2.84, CI 0.88–9.14, P value 0.080). Age,
baseline phosphorus, and baseline iPTH did not predict
successful calcium acetate control of serum phosphorus
levels. During eight weeks of follow-up, median numbers
of weeks with the serum phosphorus goal attained were
5 weeks for calcium acetate, and 1 week for sevelamer
hydrochloride. Median numbers of weeks of goal attain-
ment were 7 and 7 for the serum calcium goal, and 4 and
Table 3. Average values (Cavg) during weeks 1 to 8 and weeks 5 to 8
by treatment group
Mean ± standard deviation
Time frame Treatment group Phosphorus Calcium Ca × P
Weeks 1 to 8 Calcium acetate 5.5 ± 1.5 9.5 ± 0.7 52.7 ± 14.2
Sevelamer HCl 6.8 ± 1.6 8.9 ± 0.5 60.4 ± 14.1
P valuea 0.0006 <0.0001 0.022
Weeks 5 to 8 Calcium acetate 5.5 ± 1.7 9.6 ± 0.8 52.7 ± 16.5
Sevelamer HCl 6.4 ± 1.6 9.0 ± 0.4 57.3 ± 13.9
P valuea 0.038 <0.0001 0.42
aFrom linear regression model. [Units: serum phosphorus (mg/dL), serum cal-
cium (mg/dL), Ca × P product (mg2/dL2); to convert values for phosphorus to
millimoles per liter, multiply by 0.32; to convert values for calcium to millimoles
per liter, multiply by 0.25; to convert values for Ca × P to mmol2/L2 multiply by
0.08].
1 for Ca × P product goal, respectively. Treatment com-
parisons by ordinal logistic regression, adjusted for age,
baseline serum phosphorus, baseline iPTH, and other co-
variates were similar to the unadjusted results shown in
Table 4 (adjusted P values of 0.0023, 0.13, and 0.011 for
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Table 4. Number of subjects by treatment group attaining the
treatment goal for a given number of weeks
Number of weeks
goal attaineda
P
Outcome Treatment 0c 1 2 3 4 5 6 7 8 valueb
Phosphorus Calcium acetate 8 8 2 3 1 4 6 8 7 0.0012
Sevelamer HCl 18 8 2 6 7 4 2 2 1
Calcium Calcium acetate 0 1 2 1 2 4 5 11 21 0.12
Sevelamer HCl 1 2 2 5 4 3 3 13 17
Ca × P Calcium acetate 11 7 4 1 7 5 4 4 4 0.0023
Sevelamer HCl 19 9 6 6 6 1 1 2 0
aOnly study weeks 1 to 8 are counted. Failure was assumed in weeks with
missing data.
bP value from exact Cochran-Mantel-Haenszel test for trend.
cOne calcium acetate recipient had no follow-up and is excluded.
phosphorus, calcium, and Ca × P product, respectively),
favoring calcium acetate for both phosphorus and Ca ×
P product.
Analysis of hypercalcemia and hypocalcemia
Calcium acetate recipients generally had a higher prob-
ability of postbaseline hypercalcemia and a lower prob-
ability of hypocalcemia than did sevelamer recipients
(Table 5). Varying among postbaseline weeks 1 to 8, but
with no evident time trend, 2% to 9% of calcium ac-
etate recipients were hypercalcemic, while 2% to 13%
were hypocalcemic. These proportions compare with 0%
hypercalcemic and 7% to 24% hypocalcemic among seve-
lamer hydrochloride recipients. Regression analysis con-
firmed that hypercalcemia was significantly more likely in
the calcium acetate group (summary OR 6.1, 95% CI 2.8–
13.3, treatment P value < 0.0001 in a nine-level repeated
measures ordinal logistic regression, with the same
baseline covariates outlined above). Overall, transient
hypercalcemia developed in 8 of 48 (16.7%) calcium
acetate–treated subjects. All 8 patients who experienced
hypercalcemia were receiving concomitant intravenous
vitamin D therapy. The overall results of the analysis
of calcium data were unchanged when calcium was cor-
rected for serum albumin levels.
Binder dosage
The mean daily binder dose at each week is shown in
Figure 4. By week 8, the average daily dose was 10.7 ±
7.5 capsules (7.1 ± 5.0 g/d) in the calcium acetate group
compared with 17.2 ± 9.0 capsules (6.9 ± 3.6 g/d) in the
sevelamer hydrochloride group. In repeated measures re-
gression models, calcium acetate recipients received a sig-
nificantly fewer pills each day (P value 0.0017) with the
difference increasing over time (P value for the two d.f.
treatment-by-time interaction < 0.0001).
Impact of compliance on treatment effects
Compliance was defined by weekly pill counts. Sum-
mary compliance during the entire follow-up period (per-
cent of all prescribed pills not returned by the patient)
was also examined. Weekly mean compliance varied only
from 66% to 76% over the eight weeks with no time
trend, and little difference between the calcium acetate
group and the sevelamer hydrochloride group. However,
individual patient compliance varied substantially, with
patients’ average compliance over the eight weeks 69%
± 22% (mean ± SD) in the calcium acetate group, and
71% ± 19% in the sevelamer hydrochloride group. Com-
pliance was reported only for 83% of all patient weeks,
and this analysis omitted weeks with a missing report. Es-
timated treatment effects were nearly the same whether
the subset with compliance data or all patients were in-
cluded. With “goal attained” as the outcome, compli-
ance terms were then included in regression models.
For both serum phosphorus and the Ca × P product,
higher levels of either time-varying or average compli-
ance significantly increased the probability of attaining
the goals. However, compliance did not significantly af-
fect the probability of attaining the serum calcium goal.
In other models with the “goal attained” outcome, the in-
teraction of compliance and treatment was never signifi-
cant, implying that the observed differences in outcomes
between calcium acetate– and sevelamer-treated subjects
were unaffected by issues of compliance. Compliance was
also examined as a predictor of the number of weeks
with goal attained, and had qualitatively the same re-
sults as above: better compliance predicted a larger num-
ber of successful weeks, but had little impact upon the
highly significant treatment effect that favored calcium
acetate.
iPTH levels
Intact PTH levels were measured at baseline, weeks 4
and 8. For analysis, iPTH values were log10-transformed.
Baseline values did not differ significantly (t test P value
0.15) and, as an adjustment variable for the primary “goal
attained” outcomes, baseline iPTH was never statistically
significant (Table 2). In the calcium acetate group, geo-
metric mean (GM) iPTH declined 37% from baseline to
week 4, but only 6% more in weeks 4 to 8. In the seve-
lamer group, GM iPTH declined 6% from baseline to
week 4, and 11% in weeks 4 to 8. Separately at 4 and 8
weeks, linear regression was used to compare GM iPTH
between calcium acetate and sevelamer recipients. There
was a significant treatment effect on iPTH only at 4 weeks
(week 4 GM values: 131 pg/mL and 158 pg/mL for calcium
acetate and sevelamer, respectively; covariate-adjusted P
value 0.0034). There was no significant difference in GM
iPTH levels between the two groups at week 8. Adjust-
ment for average compliance had no impact upon these
results. Individual patient data for iPTH levels at baseline
and week 8 are shown in Figure 5.
Qunibi et al: CARE Study 1921
Table 5. Number and percent of subjects with hypocalcemia, normal serum calcium, and hypercalcemia by treatment group and week
Calcium acetate Sevelamer HCl
Week Hypo-calcemia Normal Hyper-calcemia Hypo-calcemia Normal Hyper-calcemia
0 11 (22.9%) 37 (77.1%) 0 (0.0%) 12 (24.0%) 38 (76.0%) 0 (0.0%)
1 4 (8.5%) 42 (89.4%) 1 (2.1%) 9 (18.4%) 40 (81.6%) 0 (0.0%)
2 3 (6.4%) 42 (89.4%) 2 (4.3%) 12 (24.0%) 38 (76.0%) 0 (0.0%)
3 2 (4.3%) 44 (93.6%) 1 (2.1%) 9 (18.0%) 41 (82.0%) 0 (0.0%)
4 2 (4.3%) 41 (89.1%) 3 (6.5%) 9 (19.1%) 38 (80.9%) 0 (0.0%)
5 4 (8.7%) 40 (87.0%) 2 (4.3%) 9 (20.0%) 36 (80.0%) 0 (0.0%)
6 6 (13.0%) 38 (82.6%) 2 (4.3%) 5 (11.1%) 40 (88.9%) 0 (0.0%)
7 4 (8.7%) 38 (82.6%) 4 (8.7%) 8 (17.8%) 37 (82.2%) 0 (0.0%)
8 1 (2.2%) 42 (91.3%) 3 (6.5%) 3 (6.7%) 42 (93.3%) 0 (0.0%)
Serum bicarbonate
Weekly serum bicarbonate data were analyzed as mean
concentrations (Fig. 6A), and also as “alert level attained”
when values were below a threshold of 17 mEq/L or a
more stringent lower limit of 22 mEq/L (Fig. 6B). During
weeks 1 to 8, mean serum bicarbonate levels were 20.4
to 21.9 mEq/L with calcium acetate and 19.2 to 20.2 with
sevelamer hydrochloride. By the end of the 8 weeks, the
serum bicarbonate level increased to 21.0 ± 2.6 mEq/L
(mean ± SD) with calcium acetate, while it decreased to
19.3 ± 2.7 with sevelamer hydrochloride. Baseline pro-
portions of patients below 17 mEq/L were 14.9% for cal-
cium acetate and 16.0% for sevelamer. In weeks 2 to 8,
these proportions were 14.9% to 22.2% for sevelamer,
but only 0 to 8.5% for calcium acetate. Baseline propor-
tions below 22 mEq/L were 72.3% and 80.0% for calcium
acetate and sevelamer. In weeks 2 to 8, these proportions
were 72.3% to 86.7% for sevelamer compared with 45.7%
to 65.2% for calcium acetate. Thus, during treatment,
relatively few subjects reached the lowest threshold of
17 mEq/L for serum bicarbonate, but this was more likely
with sevelamer. Subjects in both treatment groups often
had serum bicarbonate below 22 mEq/L, but this was
much more common with sevelamer. Moreover, mean
serum bicarbonate levels were always higher with calcium
acetate. In repeated measures regression models, main
effects showed significantly better results for calcium ac-
etate (P values < 0.0001 for all three serum bicarbonate
outcomes).
Adverse events
There were no significant differences between the two
treatment groups in the overall incidence of adverse
events or serious adverse events. None of the serious ad-
verse events was related to treatment with study drug.
Moreover, there was no significant difference between
the groups in the overall incidence or subjective symp-
tom scores for gastrointestinal side effects.
DISCUSSION
CARE is the first study to compare the efficacy
of calcium acetate and sevelamer in a randomized,
double-blind fashion in hyperphosphatemic hemodialysis
0 1 2 3 4 5 6 7 8
Treatment week
0
8
10
12
14
16
18
20
N
um
be
r o
f c
ap
su
le
s/
da
y
Fig. 4. Mean daily binder dose at each treatment week. Daily binder
dose (mean ± SE) during each treatment week for calcium acetate
(open circles) and sevelamer hydrochloride (closed diamonds). By re-
peated measures regression models, the prescribed number of capsules
per day was significantly higher for the sevelamer hydrochloride group
than for calcium acetate group (P value 0.0017). The mean daily dose
of sevelamer hydrochloride was significantly higher than the preceding
week at each treatment week except week 7. In contrast, the mean daily
dose of calcium acetate did not increase significantly between weeks af-
ter week 2.
patients. Calcium acetate was significantly more effec-
tive than sevelamer in controlling serum phosphorus and
Ca × P product. In the calcium acetate group mean serum
phosphorus was at or below 5.5 mg/dL after only three
weeks of treatment, while the mean serum phosphorus
in the sevelamer group never reached the target level,
despite steady dose escalation. We chose to use the 403-
mg size sevelamer capsules rather than 800-mg pills be-
cause use of the former was required for performance of
a double-blind study (calcium acetate pills were placed
in hard gelatin capsules identical to the sevelamer cap-
sules). The starting dose of sevelamer was defined accord-
ing to the manufacturer recommendations for patients
not currently receiving phosphate binders (i.e., our study
patients at the end of the washout phase). Moreover, the
daily prescribed dose of sevelamer hydrochloride at week
8 (6.9 ± 3.6 g/d) is comparable to doses employed in long-
term binder trials [9]. Our results contrast with a previous
open-label study, which suggested that, despite a higher
mean serum phosphorus in sevelamer-treated patients,
1922 Qunibi et al: CARE Study
0
100
200
300
400
500
600
700
iP
TH
, p
g/
m
L
Baseline Week 8 Baseline Week 8
Calcium acetate Sevelamer HCI
*
*
Fig. 5. Parathyroid hormone levels at base-
line and during treatment with calcium acetate
or sevelamer hydrochloride. Scatter plots
of the intact parathyroid hormone (iPTH)
levels at baseline and at week 8 during
treatment with either calcium acetate (open
circles) or sevelamer (closed circles). Diago-
nal lines connect the baseline and week 8 val-
ues for individual subjects. The vertical line
adjacent to each scatter plot displays the mean
± SD. At baseline, the mean iPTH level was
not significantly different between the calcium
acetate group and the sevelamer group (P
value 0.15). Treatment with either binder re-
sulted in a significant decrease in iPTH levels
at week 8 compared with the respective base-
line values (∗P value < 0.01). However, there
was no significant difference between the two
groups with regard to mean iPTH levels at
week 8 (P value 0.12) in a covariate-adjusted
generalized linear model. To convert serum
iPTH to picomoles/liter, multiply by 0.1.
both binders were equally efficacious [5]. In our study,
inadequate phosphorus control in the sevelamer group
could not be explained by differences in compliance with
binder therapy as measured by pill counts. In the absence
of a formal balance study it is not possible to definitively
state that calcium acetate is a more efficacious phosphate
binder than sevelamer. Better control of serum phospho-
rus in the calcium acetate group might also be explained
by a decrement in the release of phosphorus from bone as
the result of better correction of metabolic acidosis [10].
Data were also analyzed using serum calcium corrected
for albumin concentration. The findings were essentially
unchanged with regard to the incidence of hypercalcemia,
hypocalcemia, as well as the Ca × P product results. This
finding is in accord with a recent study that recommended
abandonment of correction formulas in favor of the use
of uncorrected calcium, because none of the published
formulas for albumin correction better predict ionized
calcium in dialysis patients compared with simply utiliz-
ing the total serum calcium values [12].
In the CARE Study, hypercalcemia occurred only
in calcium acetate–treated patients. Transient hypercal-
cemic episodes tended to occur at relatively low doses
of calcium acetate, and only in patients treated with in-
travenous vitamin D. It is possible that more judicious
use of intravenous vitamin D preparations may lead to
a reduction in the incidence of hypercalcemia associated
with calcium acetate treatment. Some investigators have
raised concerns about the potential risk of hypercalcemia
and cardiovascular calcification with calcium-containing
binders [5, 9, 13, 14]. Although these hypotheses remain
unsubstantiated [15], they are based on observational
studies, which suggest a correlation between vascular cal-
cification or arterial stiffness and the prescribed dose of
calcium-containing binder [13, 14]. However, it is possible
that observed correlations between arterial calcification
and prescribed binder dose are the result of refractory
hyperphosphatemia rather than a complication of treat-
ment with calcium-containing phosphate binders per se.
Indeed, because compliance with phosphate binder ther-
apy is often poor in hyperphosphatemic dialysis patients,
the findings in the studies are difficult to interpret given
that the prescribed dose may not be an accurate mea-
sure of consumed binder dose [16]. In the CARE Study,
although weekly mean serum calcium levels were sig-
nificantly higher during calcium acetate treatment, they
consistently remained well within the usual normal range.
The frequency of hypercalcemia in the CARE Study was
much lower than previously reported. This observation
may be explained by the fact that, unlike previous stud-
ies [7, 17], we maintained the dialysate calcium level at 2.5
mEq/L throughout the treatment period. Our finding that
hypercalcemia developed only in patients receiving con-
comitant therapy with calcium acetate and intravenous
vitamin D analogs suggests that the higher prevalence of
hypercalcemia in other studies may be the result of inap-
propriate use of these drugs. In this regard, in the Treat-to-
Goal study most of the calcium-containing binder treated
patients received calcitriol therapy, despite the presence
of only mild hyperparathyroidism at baseline [9]. In or-
der to achieve the therapeutic goals for iPTH and serum
phosphorus with avoidance of hypercalcemia, a more
logical treatment regimen would have been the use of
escalating doses of calcium-containing phosphate binder
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Fig. 6. Serum bicarbonate levels during
treatment with calcium acetate or sevelamer
hydrochloride. Mean serum bicarbonate lev-
els at baseline and weekly during treatment
with either calcium acetate (open circles) or
sevelamer hydrochloride (closed diamonds)
(A). At baseline, serum bicarbonate was not
significantly different between the calcium ac-
etate and sevelamer hydrochloride groups (P
value 0.11). However, during treatment mean
serum bicarbonate levels were significantly
lower in the sevelamer group than in the
calcium acetate group (P value < 0.0001 by
covariate-adjusted repeated measures regres-
sion). Observed and model-estimated per-
cent of subjects with serum bicarbonate <22
mEq/L by treatment group and week (B).
Main treatment effect: P value < 0.0001.
without exogenous vitamin D therapy, because this ap-
proach has been shown to result in adequate control of
both serum phosphorus and iPTH in most patients [18].
Administration of calcitriol in the setting of moderate hy-
perparathyroidism might also adversely impact phospho-
rus control by increasing intestinal absorption of calcium
and phosphate [19].
The potential risks of hypercalcemia associated with
calcium-containing phosphate binders may have been
overemphasized since virtually all studies have failed to
find a correlation between elevated calcium levels per se
and increased mortality in the dialysis population [1, 20];
unless the serum calcium is chronically elevated to levels
exceeding 11 mg/dL [abstract; Chertow et al, J Am Soc
Nephrol 11: 560A, 2000]. In a recent study of hemodial-
ysis patients, mortality risk was found to increase with
each 1 mg/dL increase in serum calcium level [21].
However, the strength of the association was weak and
became nonsignificant after adjustment for confounding
variables such as serum phosphorus [abstract; Klassen
et al, JAMA 288:695–696, 2002]. A recent analysis of over
70,000 hemodialysis patients found that the risk of cardio-
vascular disease was actually reduced in patients in the
highest quintile of serum calcium compared with those
in the lowest quintile [abstract; Mazess et al, J Am Soc
Nephrol 13:387A, 2002].
In contrast, increased Ca × P product has been inde-
pendently associated with increased risk of death in dial-
ysis patients [1]. In this regard, it should be noted that in
the CARE Study, despite somewhat higher mean serum
calcium levels, calcium acetate–treated patients had con-
sistently lower Ca × P products than sevelamer-treated
patients. Even among the subgroup of patients with base-
line Ca × P products exceeding 70 mg2/dL2, treatment
with calcium acetate resulted in a more rapid reduction of
the Ca × P product than treatment with sevelamer (data
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not shown). Moreover, fewer calcium acetate–treated pa-
tients experienced an increase in Ca × P product above
the baseline value during the first month of therapy (data
not shown).
In the CARE Study, hypocalcemia occurred signif-
icantly more often during sevelamer treatment. The
pathogenesis of sevelamer-induced hypocalcemia has not
been carefully studied. Because dialysate calcium of 2.5
mEq/L results in no net calcium flux [22], and dialysis
patients have reduced intestinal absorption of dietary
calcium [23], although formal balance studies were not
performed, it is possible that simple withdrawal of
calcium-containing phosphate binders was sufficient to
cause a net negative calcium balance and hypocalcemia
in 50% of sevelamer-treated patients. In this regard, de-
creasing dialysate calcium from 3.0 to 2.5 mEq/L for a
one-year period has been shown to result in an average
100 pg/mL increase in iPTH levels [24]. The long-term
sequelae of chronic hypocalcemia in sevelamer-treated
patients are currently unknown. Nonetheless, hypocal-
cemia should probably be avoided since an independent
association between chronic hypocalcemia and increased
mortality in dialysis patients has been reported [20, 25]. In
dialysis patients with serum calcium less than 8.8 mg/dL,
relative risk of death increased three-fold [20]. Accord-
ingly, it has been recommended that patients treated with
sevelamer receive a nighttime supplement of 1 g of ele-
mental calcium to prevent hypocalcemia [26]. When cal-
cium carbonate is given on an empty stomach, as much
as 40% of the calcium may be absorbed [27]. In contrast,
only about 15% to 20% of the elemental calcium is ab-
sorbed when calcium acetate is taken with meals [28].
Thus, patients taking sevelamer with supplemental cal-
cium carbonate at night are likely to absorb as much
calcium as patients taking calcium acetate with meals as
a phosphate binder. The rationale for treatment of pa-
tients on sevelamer with a nighttime calcium supplement
is not entirely clear. It would be more logical to admin-
ister required calcium supplements with meals as part of
an overall phosphate-binding regimen.
We found no evidence of oversuppression of iPTH in
calcium acetate–treated patients because the PTH levels
at week 8 were not significantly different in sevelamer-
treated patients. Baseline iPTH was not significantly dif-
ferent between the two groups and inclusion of baseline
iPTH as covariate in the repeated measures logistic re-
gression model had no effect on the observed benefit of
treatment with calcium acetate with regard to better con-
trol of serum phosphorus or Ca × P product.
Calcium acetate and sevelamer hydrochloride were
both well tolerated, and gastrointestinal side effects were
similar. However, we confirmed previous reports that
treatment with sevelamer leads to reduction in serum
bicarbonate levels [7, 9, 29]. Analysis of the proposed
phosphate-binding mechanism for sevelamer hydrochlo-
ride indicates that one molecule of hydrochloric acid is
released in exchange for every molecule of phosphate
bound. Data from our laboratory suggest that treatment
with sevelamer hydrochloride results in a significant in-
crease in the daily acid load. Normal rats fed a diet
containing sevelamer hydrochloride develop a significant
decrease in urine pH and a significant increase in uri-
nary ammonium excretion as measured by ion-specific
electrode (unpublished observation). Acidemia should
clearly be avoided in patients with chronic renal failure
because it has two major systemic consequences [30].
Metabolic acidosis has several effects on bone, causing
physiochemical dissolution of bone and cell-mediated
bone resorption (inhibition of osteoblast and stimula-
tion of osteoclast function) [10, 30]. Chronic metabolic
acidosis also induces a net-negative nitrogen and total
body protein balance, which improve following bicarbon-
ate supplementation [30, 31, 32]. The data suggest that
metabolic acidosis is both catabolic and antianabolic [30].
These considerations underscore the urgent need for fur-
ther studies of acid-base balance during long-term treat-
ment with sevelamer hydrochloride.
One of the limitations of this study is the relatively short
8-week treatment period. However, the doses of calcium
acetate and sevelamer used in the CARE Study were sim-
ilar to those employed in longer-term phosphate binder
studies [9]. Moreover, a recent cross-sectional study of
hemodialysis patients treated with sevelamer hydrochlo-
ride for longer than one year (mean 23 months, range
13 to 40 months), revealed that in comparison to pa-
tients treated with calcium-containing phosphate binders,
sevelamer-treated patients had higher serum phosphorus
levels (6.5 ± 1.2 vs. 5.4 ± 1.5 mg/dL; P < 0.05), higher
Ca × P products (62.1 ± 16 vs. 49.7 ± 14.6 mg2/dL2; P <
0.05), and lower serum bicarbonate levels (18.6 ± 2.7 vs.
20.3 ± 1.8 mEq/L; P < 0.05) [abstract; Ciampi MA et al,
J Am Soc Nephrol 13:586A, 2002]. Very similar findings
were reported in another cross-sectional study compar-
ing hemodialysis patients treated with either sevelamer
or calcium-containing binders [abstract; Block GA, J Am
Soc Nephrol 12:761A, 2001].
The recently published Treat-to-Goal Study, an open-
label comparison of calcium salts to sevelamer, suggested
that calcium salt usage may be associated with progres-
sion of vascular calcification in dialysis patients [9]. How-
ever, information was not provided regarding the use of
nighttime calcium supplements in the sevelamer group or
the dialysate calcium concentrations employed in the two
treatment groups. The fact that 17% of sevelamer-treated
patients in this study developed hypercalcemia suggests
that they may have been treated with higher dialysate
calcium or received dietary calcium supplements. If cal-
cium supplements were prescribed to sevelamer-treated
patients to prevent hypocalcemia as in other studies by
these investigators [26], it would be difficult to draw any
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firm conclusions regarding the possible pathogenic role of
calcium loading from calcium salts in the progression of
cardiovascular calcification. Furthermore, calcium load-
ing from the use of calcium-containing binders is only one
possible explanation for the slower progression of cardio-
vascular calcification observed in sevelamer-treated pa-
tients. This finding might also be explained by the marked
difference in total and low-density lipoprotein (LDL)
cholesterol levels between the two treatment groups,
whereby the calcium-containing binder group had mean
LDL cholesterol levels nearly twice as high as the seve-
lamer group. Sevelamer is a bile acid sequestrant which,
when given in large doses, can significantly reduce choles-
terol levels [8]. It is quite possible that the beneficial ef-
fect of sevelamer on the progression of cardiovascular
calcification in the Treat to Goal Study [9] was the result
of better lipid control because LDL cholesterol has been
implicated as an important contributing factor in the pro-
gression of cardiovascular disease in the general popula-
tion. Moreover, lowering the LDL level with HMG-CoA
reductase inhibitors have been shown to significantly re-
duce coronary calcification after only one year of treat-
ment [33, 34]. Thus, the important issue of increased
cardiovascular calcification in dialysis patients can only
be addressed by well-designed, double-blind studies
which control for not only the type of phosphate binder,
but also for the myriad risk factors potentially associated
with vascular calcification, including dialysate calcium
level, vitamin D usage, and treatment of hyperlipidemia
[15].
CONCLUSION
The cost of phosphate binder therapy remains an im-
portant issue. Based on week 8 doses and average whole-
sale prices for PhosLo and Renagel [35], the projected
annual per patient cost for treatment with calcium ac-
etate would be $732 compared to $4,283 for sevelamer.
Thus, if sevelamer were to be adopted as the first-line
phosphate binder, the cost for treatment of the roughly
270,000 dialysis patients in the United States would in-
crease by over 1 billion dollars per year. Although the
lipid-lowering effect of sevelamer may have a beneficial
role in slowing the progression of cardiovascular calcifi-
cation in dialysis patients [9], cost-benefit analysis reveals
that combined treatment with an HMG-CoA reductase
inhibitor and calcium-containing phosphate binders
would be a far more cost-effective alternative. Given the
superior efficacy of calcium acetate for control of serum
phosphorus and Ca × P product, it appears to be the
more cost-effective choice as first-line treatment for hy-
perphosphatemia in patients with ESRD on maintenance
dialysis. Nevertheless, in the occasional patient who de-
velops persistent hypercalcemia during calcium acetate
treatment despite appropriate reduction in vitamin D
dosage, it may be prudent to reduce the dose of calcium
acetate and add a non–calcium-containing binder such as
sevelamer hydrochloride [36].
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